Claim 70% Off TipRanks Premium
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Stay ahead of the market with the latest news and analysis and maximize your portfolio's potential
An update from Lexeo Therapeutics, Inc. ( (LXEO) ) is now available.
On January 12, 2026, Lexeo Therapeutics reported positive interim Phase I/II data from its HEROIC-PKP2 trial evaluating LX2020, an AAV-based gene therapy for PKP2-associated arrhythmogenic cardiomyopathy, showing the treatment was generally well tolerated in ten dosed participants with no clinically significant complement activation and no study discontinuations. Cardiac biopsies from seven participants demonstrated robust, dose-dependent PKP2 transduction and expression, with mean PKP2 protein levels rising 93% in the low-dose cohort and 162% in the high-dose cohorts, and clinical measures in eight participants with at least six months of follow-up indicated stabilization or improvement in arrhythmia burden, including reductions in non-sustained ventricular tachycardia and premature ventricular contractions, alongside stable cardiac function and improved patient-reported outcomes at higher doses. Enrollment in HEROIC-PKP2 was completed in the fourth quarter of 2025, with additional biopsy data and 12‑month outcomes from high-dose participants expected in 2026, positioning LX2020 as a potentially important new therapy candidate in a genetically driven cardiomyopathy segment with significant unmet need and reinforcing Lexeo’s strategic focus on gene therapy for cardiovascular disease.
The most recent analyst rating on (LXEO) stock is a Buy with a $13.00 price target. To see the full list of analyst forecasts on Lexeo Therapeutics, Inc. stock, see the LXEO Stock Forecast page.
Spark’s Take on LXEO Stock
According to Spark, TipRanks’ AI Analyst, LXEO is a Neutral.
The score is held back primarily by weak financial performance (pre-revenue status, widening losses, and heavy cash burn). Offsetting factors include improving technical trend/momentum and positive corporate developments, including added capital from the $135M offering and encouraging regulatory/clinical progress. Valuation support is limited due to negative earnings and no dividend.
To see Spark’s full report on LXEO stock, click here.
More about Lexeo Therapeutics, Inc.
Lexeo Therapeutics, Inc. is a New York City-based, clinical-stage genetic medicine company focused on reshaping heart health by developing gene therapies that target the underlying genetic causes of cardiovascular diseases and other severe conditions with high unmet need. Its pipeline includes LX2020 for plakophilin-2-associated arrhythmogenic cardiomyopathy (PKP2-ACM), LX2006 for Friedreich ataxia cardiomyopathy, and additional candidates in genetic cardiac disorders.
Average Trading Volume: 1,341,185
Technical Sentiment Signal: Buy
Current Market Cap: $691.2M
For a thorough assessment of LXEO stock, go to TipRanks’ Stock Analysis page.